Phase 2 trial finds bezisterim shows safety and symptom gains in long COVID, with strongest benefits for severe fatigue, PEM, and cognitive issues.
|Articles|March 23, 2020
PsychPearls: Battling Loneliness During the COVID-19 Pandemic
Author(s)Joshua C. Morganstein, MD
What can psychiatrists do to help their patients cope with self-quarantine and isolation practices? More in this podcast.
Advertisement
We have invited Dr Joshua Morganstein, Chair of the
What can psychiatrists do to help their patients cope with self-quarantine and isolation practices?
Have more COVID concerns and clinical tips? Email us at
Advertisement
Related to this article
Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.
Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Psych Consult: TSH Testing in New-Onset Depression. An Endocrinologist’s Guidance for Psychiatrists
2
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
3
New Phase 2 Data on Bezisterim for the Treatment of Long COVID
4
When Antidepressants Stop Working: Understanding Tachyphylaxis in Clinical Practice
5